| Date | Title | Description |
| 28.08.2026 | BioCryst is profitable. Now it wants to buy more rare disease drugs | BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals.
As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly steppi... |
| 19.08.2026 | BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment | BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones.
Alesta Therapeutic’s lead drug is a potential treatment for hypophosphatasia (HPP).
The deal bolsters BioMarin’s u... |
| 18.08.2026 | The startup using AI to help rare disease families develop custom treatments | Nome is building an AI-powered drug development service for ultra-rare disease patients, helping families identify potential treatments and map out a path from diagnosis to clinical development.
The startup targets patient groups often over... |
| 11.08.2026 | Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio | Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million.
Deal centers around Actio’s lead drug for KCNT+ epilepsy, ABS-1230.
The deal expands Jazz’s rare epilepsy portfolio, with ABS-1230 recently accepted into an FDA pro... |
| 10.08.2026 | The power of genetic testing: new screening methods are catching rare diseases before symptoms start | Genetic testing is helping rare disease patients get answers earlier, sometimes before symptoms appear, opening the door to treatment before irreversible damage occurs.
For families, a genetic diagnosis can provide much more than a name for... |
| 06.08.2026 | CAMP4 advances rare disease treatment for SYNGAP1 into human trials | CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders.
The trial will enroll at least 30 children ages 2 to 18 and use a... |
| 31.07.2026 | New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn | New Medicaid work requirements could put rare disease patients at risk of losing coverage, even when their medical conditions prevent them from consistently working.
Advocates warn that vague exemption rules and differing state policies cou... |
| 22.07.2026 | Neurimmune closes licensing deal of up to USD425 million |
Cliramitug is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthyretin cardiomyopathy (ATTR-CM). In 2022, Neurimmune entered ... |
| 28.05.2026 | Solstice Secures $21M for AI-Native Pharmaceutical Marketing Platform
From 3 Months to 10 Days: Why Solstice Raised $21M to Automate Pharma MLR Workflows | What You Should Know
AI-native pharmaceutical marketing platform Solstice has announced a $21M Series A funding round led by Transformation Capital, bringing its total funding footprint to approximately $25M.
The financing, featuring partic... |
| 28.05.2026 | Solstice: $21 Million Series A Raised To Accelerate Pharma Commercialization | Solstice, an AI-native marketing agency focused on accelerating pharma commercialization, announced it has raised $21 million in Series A funding led by Transformation Capital with participation from Twelve Below, Virtue Ventures, and other... |
| 07.05.2026 | Rare disease families find roadmap to drug development at bootcamps | Rare disease families are increasingly driving research efforts to find treatments for their children.
Ultragenyx’s Rare Bootcamp gives advocates a roadmap for navigating drug development.
The program has helped connect families with resear... |
| 24.04.2026 | Iridius: $8.6 Million Seed Funding Raised To Build Compliance-By-Design AI Platform For Regulated Industries | Iridius, a compliance-by-design AI platform for regulated workflow execution, has raised $8.6 million in seed funding led by Chalfen Ventures, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. Separ... |
| 31.03.2026 | Efzimfotase alfa Ph3 program show positive results | Efzimfotase alfa Ph3 program show positive results
Tue, Mar 31, 2026 08:00 CET Report this content
This announcement contains inside information
31 March 2026
Efzimfotase alfa demonstrated positive results from global Phase III clinical pro... |
| 20.02.2026 | Fixed-duration Calquence combo approved in US | Fixed-duration Calquence combo approved in US
Fri, Feb 20, 2026 08:00 CET Report this content
20 February 2026
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic ... |
| 01.02.2026 | Llamas are big pharma’s secret weapon to find new drugs | Getting your Trinity Audio player ready...
By Lisa Pham, Bloomberg News
One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears flattened defiantly. A third rushes to gree... |
| 05.12.2025 | Neurimmune to receive up to $780m in extended partnership with AstraZeneca |
Neurimmune is a clinical stage biopharmaceutical company building next generation therapeutics to address protein aggregation diseases with extensive experience in amyloid depletion. Their drug candidate N1009 is a preclinical human monocl... |
| 22.09.2025 | Koselugo recommended for EU approval | Koselugo recommended for EU approval
Mon, Sep 22, 2025 08:41 CET Report this content
22 September 2025
Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1
Recommendation ba... |
| 16.07.2025 | Update on anselamimab in AL amyloidosis | Update on anselamimab in AL amyloidosis
Wed, Jul 16, 2025 08:00 CET Report this content
16 July 2025
Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis
Results did not achieve statistical significance for... |
| 24.06.2025 | Alexion Charitable Foundation Supports iHope Genetic Health Through Its Rare Belonging® Signature Initiative | Join iHope Genetic Health
Advancing equity in rare disease diagnosis through a global partnership for free genomic testing
Our work with Alexion Charitable Foundation reflects a shared belief that where a child is born should not determine ... |
| 23.06.2025 | Accelerating Plasmid Construct Development with Smart Bioreactors, Upcoming Webinar Hosted by Xtalks | www.culturebiosciences.com
In this free webinar, learn how leveraging cloud-integrated 250 mL bioreactors enables rapid and remote evaluation of plasmid fermentation processes, providing crucial early-stage data accessible anywhere, anytime... |
| 06.06.2025 | Fixed-duration Calquence approved in EU for 1L CLL | Fixed-duration Calquence approved in EU for 1L CLL
Fri, Jun 06, 2025 08:00 CET Report this content
06 June 2025
Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting
A... |
| 29.04.2025 | AstraZeneca's Calquence: A New Dawn for CLL Treatment in Europe | AstraZeneca is on the brink of a breakthrough. The European Medicines Agency (EMA) has recommended the approval of a fixed-duration regimen of Calquence (acalabrutinib) for treating chronic lymphocytic leukaemia (CLL). This recommendation, ... |
| 29.04.2025 | Fixed-duration Calquence recommended in EU for CLL | Fixed-duration Calquence recommended in EU for CLL
Tue, Apr 29, 2025 08:10 CET Report this content
29 April 2025
Fixed-duration Calquence-based regimens recommended for approval
in the EU by CHMP for 1st-line chronic lymphocytic leukaemia
R... |
| 26.04.2025 | Granite Bio: A New Force in Immunology with $100 Million Backing | Granite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro... |
| 25.04.2025 | Granite Bio: Immunology Company Debuts With $100 Million In Funding | Granite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 20.02.2025 | Stratevi Launches Medical Affairs Practice to Deliver Integrated Medical, Evidence, and Value Strategy | Sean Brugger, PhD
With the addition of Sean Brugger, PhD, Stratevi is now capable of fully delivering integrated HEOR, Pricing/Market Access, and Medical solutions for its biopharma and medical device client partners.
SANTA MONICA, Calif., ... |
| 18.02.2025 | AstraZeneca's Board Transformation: A New Era in Cancer Care | AstraZeneca is undergoing a significant transformation. The biopharmaceutical giant is set to welcome Karen Knudsen as a Non-Executive Director. This move is more than just a boardroom shuffle; it’s a strategic play in the complex game of c... |
| 18.02.2025 | Directorate Change | Directorate Change
Tue, Feb 18, 2025 08:00 CET Report this content
18 February 2025
Non-Executive Board Changes
AstraZeneca PLC announced today that Karen Knudsen will be proposed for election as a Non-Executive Director at the Company's An... |
| 29.01.2025 | Prevent Blindness Declares February as Age-related Macular Degeneration and Low Vision Awareness Month to Educate Public on the Eye Disease and Available Support Programs | February declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness to educate public on one of the leading causes of vision loss.
Prevent Blindness provides a wealth of free educational resources... |
| 12.01.2025 | Prudentia Sciences: AI-Based Life Sciences Marketplace Company Raises $7 Million | Prudentia Sciences, an AI-based technology platform for life sciences, announced its public launch, supported by $7 million in funding. This funding round was led by GV, with participation from Iaso Ventures and Virtue.
The company aims to ... |
| 11.01.2025 | Prudentia Sciences: A New Dawn in Life Sciences Dealmaking | In the bustling corridors of Cambridge, Massachusetts, a new player is making waves in the life sciences arena. Prudentia Sciences has emerged with a mission: to revolutionize how biopharma companies navigate the complex world of drug devel... |
| 09.01.2025 | Prudentia Sciences Launches with $7M in Funding to Transform the Life Sciences Marketplace for Dealmaking | CAMBRIDGE, Mass.–(BUSINESS WIRE)–January 9, 2025–
Prudentia Sciences, an AI-powered technology platform for life sciences announced today its public launch, supported by $7 million in funding. The funding round was led by GV, with participa... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 26.10.2024 | Monopar Therapeutics: A High-Stakes Gamble in Biotech | Monopar Therapeutics is riding a rollercoaster. The company’s stock surged over 400% in a single day, fueled by a licensing deal with AstraZeneca. This spike has drawn attention, but it also raises questions. Is this a genuine opportunity o... |
| 25.10.2024 | Monopar Therapeutics Skyrockets 400% on Licensing Deal Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 d... |
Monopar Therapeutics (NASDAQ: MNPR) saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000.
This s... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 18.10.2024 | Positive progress in addressing unmet medical needs |
The FDA has granted Fast Track designation to Neurimmune’s partner Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy... |
| 10.09.2024 | Accelerating Clinical Product Development through Centralized Content Work Streams, Upcoming Webinar Hosted by Xtalks | lifesciences.transperfect.com
In this free webinar, learn how centralizing localization of clinical documentation can drastically reduce timelines for global studies. Attendees will learn practical methods for leveraging technology automati... |
| 05.09.2024 | Raising Awareness and Empowering Patients: The Fight Against Kidney Disease | Kidney disease is a silent predator. It lurks in the shadows, often unnoticed until it strikes. The statistics are alarming. Approximately 35.5 million adults in the U.S. have chronic kidney disease (CKD), yet around 90% are unaware of thei... |
| 03.09.2024 | NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024 | PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on Sep... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 15.07.2024 | AstraZeneca Closes Acquisition of Amolyt Pharma | Amolyt Pharma, an Ecully, France global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, announced that its previously announced acquisition by global pharmac... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 10.05.2024 | Geisinger enrolls first patient in amyloid cardiomyopathy trial | DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The team is also the first to in the U.S. to screen... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 01.05.2024 | Prevent Blindness to Host 13th Annual Focus on Eye Health Summit, a Two-Day Virtual Interactive Event, with theme of "Being Seen and Heard" | Registration open for free 13th Annual Prevent Blindness Focus on Eye Health Summit, held virtually, July 10 and 11, 2024.
National nonprofit Prevent Blindness to hold the 2024 Focus on Eye Health Summit, a free virtual interactive event, J... |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 09.04.2024 | Clinical success for Neurimmune |
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowin... |
| 25.03.2024 | Ultomiris approved in the US for NMOSD | Ultomiris approved in the US for NMOSD
Mon, Mar 25, 2024 08:00 CET Report this content
25 March 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
First and only long-acting C5 ... |
| 18.03.2024 | AstraZeneca купит Amolyt Pharma за $1,05 млрд | По условиям сделки AstraZeneca купит Amolyt Pharma за общую сумму до $1,05 млрд без учета денежных средств и долгов.
В сумму вознаграждения входит аванс в размере $800 млн долларов при закрытии сделки. Акционеры Amolyt Pharma также получат ... |
| 18.03.2024 | AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline | Amolyt development portfolio includes Phase III asset with potential to address significant unmet need in patients with chronic hypoparathyroidism
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complemen... |
| 14.03.2024 | Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca | Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire... |
| 14.03.2024 | AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda | AstraZeneca is bolstering its rare disease pipeline with a deal to buy Amolyt Pharma, a biotech company in late-stage development with a therapy designed to treat a rare hormone deficiency whose only FDA-approved treatment will soon cease p... |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Development at 9th RARE Drug Development Symposium | RARE Drug Development Symposium
The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to advance th... |
| 29.02.2024 | Often misdiagnosed, it's time to raise awareness of the rare disease amyloidosis | (BPT) - What started as a dream trip to Hawaii became a medical turning point for Sally Cox. While snorkeling in the crystal-clear waters, she suddenly found it difficult to breathe and nearly drowned. Shocked, scared and confused, she imme... |
| 07.01.2022 | Neurimmune and AstraZeneca join forces | |
| 20.09.2021 | Genomenon Announces Collaboration to Accelerate Genetic Diagnosis for Rare Disease Patients | “We are encouraged by our collaboration with Genomenon and the potential to advance our collective efforts to enable earlier diagnosis and treatment for people living with rare diseases.”
ANN ARBOR, Mich. (PRWEB) September 20, 2021
Genomeno... |
| 15.07.2021 | Alexion Pharmaceuticals : AstraZeneca receives final regulatory clearance for the proposed acquisition of Alexion from the UK's Competition and Markets Authority | The UK Competition and Markets Authority has cleared AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion). As a result, the acquisition is expected to close on 21 July 2021.
Following closing, the new AstraZeneca sh... |
| 14.07.2021 | AstraZeneca : receives final regulatory clearance for the proposed acquisition of Alexion from the UK's Competition and Markets Authority | PUBLISHED14 July 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JUR... |
| 14.07.2021 | AstraZeneca : receives final regulatory clearance for the proposed acquisition of Alexion from the UK's Competition and Markets Authority (Form 6-K) | AstraZeneca receives final regulatory clearance for the proposed acquisition of Alexion from the UK's Competition and Markets Authority
The UK Competition and Markets Authority has cleared AstraZeneca's proposed acquisition of Alexion Pharm... |
| 14.07.2021 | AstraZeneca-Alexion transaction cleared in the UK | AstraZeneca-Alexion transaction cleared in the UK Wed, Jul 14, 2021 08:14 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A V... |
| 07.07.2021 | Alexion Pharmaceuticals : AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion | AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion) has achieved an important step towards completion by having cleared the European Commission review.
The clearance follows competition clearances in the United Sta... |
| 06.07.2021 | AstraZeneca : receives clearance from the European Commission for the proposed acquisition of Alexion (Form 6-K) | AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion
AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion) has achieved an important step towards completion by having cl... |
| 07.06.2021 | ALEXION PHARMACEUTICALS, INC.
Alexion Pharmaceuticals : Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with par... |
| 07.06.2021 | Alexion Pharmaceuticals : Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with par... |
| 04.06.2021 | AstraZeneca appoints new Chief Financial Officer | AstraZeneca appoints new Chief Financial Officer Fri, Jun 04, 2021 08:00 CET
4 June 2021 07:00 BST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO... |
| 04.05.2021 | ALEXION PHARMACEUTICALS, INC. : Other Events (form 8-K) | Item 8.01 Other Events.
As previously disclosed, on December 12, 2020, Alexion Pharmaceuticals, Inc., a Delaware corporation ("Alexion"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with AstraZe... |
| 19.04.2021 | ALEXION PHARMACEUTICALS, INC.
Alexion Pharmaceuticals : AstraZeneca receives US clearance of proposed acquisition of Alexion | AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review. This follows the conclusion of the waiting period under the Ha... |
| 16.03.2021 | FTC pledges to aggressively crack down on pharma mergers | The Federal Trade Commission said Tuesday that it’s setting up an international working group to more closely evaluate pharmaceutical company mergers in light of concerns around drug pricing and anticompetitive b... |
| 04.02.2021 | Alexion Pharmaceuticals : Reports Fourth Quarter and Full Year 2020 Results | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 were $6,069.9 million, a 22 percent increase compared to the same period in... |
| 14.01.2021 | Covid-19 roundup: Alexion's C5 inhibitor Ultomiris misses the PhIII bar; Lonza in waiting game to use ingredients in Moderna vaccine | C5 inhibition isn’t the answer to the search for treatments for severe Covid-19 after all.
Alexion is pausing enrollment to a Phase III study testing Ultomiris, the long-acting follow-on to Soliris, among patients requirin... |
| 12.12.2020 | AstraZeneca To Pay $39 Billion For Alexion — 14% Off Its All-Time High | TORONTO, ON - DECEMBER 2 - Toni Vernon poses at her Toronto home, December 2, 2014. Vernon has a ... [+] rare blood disease called aHUS and must undergo dialysis three times a week. She needs access to Soliris, a $500,000-a-year drug that i... |
| 07.12.2020 | ATP Forms ATP V With $1 Billion in New Capital Commitments | December 7, 2020 -- ATP today announces the formation of ATP V with $1 billion in committed capital, bringing the total capital the firm has raised to $2.65 billion. The strategy for deploying ATP V aligns with the core strategy of ATP: fou... |
| 03.11.2020 | Meet the CXO – George Llado | George Llado – SVP & CIO, Alexion Pharmaceuticals
We had the opportunity to catch up with George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals and long-time CXO Advisory Board Member. George is re... |
| 12.10.2020 | ALEXION PHARMACEUTICALS, INC.
Alexion Pharmaceuticals : Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS® (ravulizumab-cwvz) 100 mg/mL formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria (P... |
| 25.09.2020 | ALEXION PHARMACEUTICALS, INC.
Alexion Pharmaceuticals : ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved ULTOMIRIS® (ravulizumab) for adults and children living with atypical hemolytic uremic syndrome (aHUS). ULTOMIRI... |
| 01.08.2020 | ALEXION PHARMACEUTICALS, INC.
Alexion Pharmaceuticals : Q2 Earnings Call July 30 2020 | Second Quarter
2020
Earnings Call
July 30, 2020
BUNNY WITH HER HUSBAND, JOE LIVING WITH PNH
F O R W A R D L O O K I N G S T A T E M E N T S
2 | D I S C L O S U R E S R A R E I N S P I R A T I O N . C H A N G I N G L I V E S .
This presentat... |
| 12.06.2020 | Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk | NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- Apple Tree Partners (ATP), a leading life sciences fund, will exit its ownership stake in Corvidia Therapeutics, a precision cardiovascular therapeutics company, with Novo Nordisk’s acquisition of... |
| 20.04.2020 | Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease | Ultomiris is a C5 complement inhibitor approved for treating paroxysmal nocturnal hemoglobinuria. It belongs to the same class as Soliris, but is designed to be used less frequently.
“Alexion has been in close contact with physicians and gl... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 28.01.2019 | After securing quick OK for PNH patients, Alexion's Ultomiris succeeds in aHUS pivotal study | About a month after the FDA gave Alexion a Christmas present in the form of an early approval for its rare blood disorder drug, Ultomiris, for patients with PNH, the drugmaker has reported positive pivotal data evaluatin... |
| 27.09.2018 | Alexion To Acquire Syntimmune, for Up To $1.2 Billion | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a a global biopharmaceutical company, is to acquire Syntimmune, a Boston, Mass.-based clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcR... |
| 21.08.2018 | FDA accepts Alexion’s application for next-generation PNH drug | ALXN1210 is a long-acting medicine with the same target as Soliris (eculizumab), for which Alexion won FDA approval for reducing red blood cell destruction – also known as hemolysis – in PNH in 2007, but which must be dosed more frequently.... |
| 21.12.2016 | More bad news for Alexion: Soliris trial fails | Rumors of possible fraud have been circulating since Alexion missed the deadline for its third quarter financial report, known as a 10-Q. These are mandated by the Securities and Exchange Commission (SEC) for all public companies.
Alexion i... |
| 08.06.2016 | Cloud Therapy Uses Watson to Help Doctors, Pharma With Diagnoses | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
San Antonio — Andre Sandoval was born with a rare genetic condition. It was five months before his physician delivered a definitive diagnosis: he had a derivative of symphalan... |
| 03.12.2015 | True North, Following the Alexion Rare Disease Playbook, Nabs $40M | Alexion Pharmaceuticals became successful by developing treatments for ultra-rare diseases, the kind hardly anybody has ever heard of. |
| - | Pioneering a more equitable future for rare disease communities | In the United States, a rare disease is defined as a disease that affects fewer than 200,000 people. Many rare diseases affect only a few thousand, a few hundred, or even just a handful of individuals. While each individual rare disease imp... |
| - | More bad news for Alexion: Soliris trial fails | Alexion Pharmaceuticals quietly reported late Wednesday that its Phase 2/3 trial of eculizumab (Soliris) had failed to reach its primary endpoint for the prevention of delayed graft function in recipients of deceased donor kidneys.
The news... |
| - | The Orphan Drug Act at 40: still critical for the treatment of rare diseases | A champion for equity in research and treatment access, Alexion Vice President for Corporate Affairs Tamar Thompson is not shy about speaking up on behalf of people living with rare diseases — and bringing her own personal experiences to be... |
| - | FDA accepts Alexion’s application for next-generation PNH drug | The Food and Drug Administration has accepted for priority review Alexion Pharmaceuticals’ new drug for a rare blood disorder.
The New Haven, Connecticut-based company said Monday that the FDA would review its application for ALXN1210, a C5... |
| - | Is evolving research in complement inhibition a key to finding new medicines for rare diseases? | An uncharted pathway
Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to treating rare diseas... |
| - | Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease | A biotech company that markets drugs for rare blood disorders plans to bring its most recently approved product into a Phase III clinical trial for Covid-19.
Boston-based Alexion Pharmaceuticals said Monday that it would start a global Phas... |
